Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Daiichi Sankyo’s ADC U3-1402 Shows Tumor Reduction in NSCLC Patients: Preliminary PI Data
Daiichi Sankyo has presented preliminary data from a PI study of its HER3 targeting antibody drug conjugate (ADC) U3-1402 in non-small cell lung cancer (NSCLC) patients, showing a reduction in tumor size in all evaluable patients. The study enrolled 23…
To read the full story
Related Article
- Daiichi Sankyo Presents Updated PI Data of ADCs DS-1062, U3-1402 for NSCLC
September 11, 2019
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





